Douglas Emmett (DEI) Q2 FFO Meet Estimates

06.08.25 00:50 Uhr

Werte in diesem Artikel
Aktien

11,90 EUR -0,06 EUR -0,50%

13,80 EUR 0,20 EUR 1,47%

70,50 EUR 1,00 EUR 1,44%

Indizes

16.905,7 PKT 29,3 PKT 0,17%

16.942,7 PKT 10,8 PKT 0,06%

7.143,6 PKT 4,6 PKT 0,06%

Douglas Emmett (DEI) came out with quarterly funds from operations (FFO) of $0.37 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.46 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this real estate investment trust would post FFO of $0.39 per share when it actually produced FFO of $0.4, delivering a surprise of +2.56%.Over the last four quarters, the company has surpassed consensus FFO estimates three times.Douglas Emmett, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $252.43 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.52%. This compares to year-ago revenues of $245.78 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.Douglas Emmett shares have lost about 20.2% since the beginning of the year versus the S&P 500's gain of 7.6%.What's Next for Douglas Emmett?While Douglas Emmett has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.Ahead of this earnings release, the estimate revisions trend for Douglas Emmett was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.34 on $251.74 million in revenues for the coming quarter and $1.45 on $1.01 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Another stock from the same industry, American Healthcare REIT (AHR), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7.This real estate investment trust is expected to post quarterly earnings of $0.40 per share in its upcoming report, which represents a year-over-year change of +21.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.American Healthcare REIT's revenues are expected to be $544.78 million, up 8% from the year-ago quarter.Should You Invest in Douglas Emmett, Inc. (DEI)?Before you invest in Douglas Emmett, Inc. (DEI), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Douglas Emmett, Inc. (DEI): Free Stock Analysis Report American Healthcare REIT, Inc. (AHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Q2 und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Douglas

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Douglas

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Douglas AG

Wer­bung

Analysen zu Douglas AG

DatumRatingAnalyst
14.08.2025Douglas NeutralUBS AG
14.08.2025Douglas BuyDeutsche Bank AG
14.08.2025Douglas BuyJefferies & Company Inc.
14.07.2025Douglas BuyDeutsche Bank AG
15.05.2025Douglas NeutralUBS AG
DatumRatingAnalyst
14.08.2025Douglas BuyDeutsche Bank AG
14.08.2025Douglas BuyJefferies & Company Inc.
14.07.2025Douglas BuyDeutsche Bank AG
15.05.2025Douglas BuyDeutsche Bank AG
15.05.2025Douglas BuyJefferies & Company Inc.
DatumRatingAnalyst
14.08.2025Douglas NeutralUBS AG
15.05.2025Douglas NeutralUBS AG
26.03.2025Douglas NeutralUBS AG
23.01.2013DOUGLAS haltenequinet AG
14.12.2012DOUGLAS haltenIndependent Research GmbH
DatumRatingAnalyst
29.01.2013DOUGLAS verkaufenIndependent Research GmbH
05.12.2012DOUGLAS verkaufenFrankfurter Tagesdienst
04.12.2012DOUGLAS verkaufenNational-Bank AG
19.11.2012DOUGLAS reduceCommerzbank Corp. & Markets
16.10.2012DOUGLAS underperformCheuvreux SA

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Douglas AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen